Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update

Rhea-AI Summary

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced a conference call on November 2, 2022, at 5:00 PM ET to discuss Q3 2022 financial results and corporate updates. This call will provide insights into the company's performance and strategic direction as it focuses on developing therapies for rare genetic diseases. The live webcast will be accessible via the company's website, along with a replay available for a year. Ultragenyx aims to deliver effective therapies promptly, addressing significant unmet medical needs in the rare disease space.

Positive

• Ultragenyx is focused on developing and commercializing therapies for rare diseases, indicating a strong market position.
• The upcoming conference call will provide an opportunity for investors to gain insights into the company's Q3 performance and strategy.

Negative

• None.

NOVATO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Wednesday, November 2, 2022, at 5:00pm ET to discuss its financial results and corporate update for the quarter ended September 30, 2022.

The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call, please register by clicking on the following link (registration link), and you will be provided with dial-in details. The replay of the call will be available for one year.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts
Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
415-475-6370
IR@ultragenyx.com

Media
Jeff Blake
415-612-7784
media@ultragenyx.com

FAQ

What will Ultragenyx discuss in its Q3 2022 earnings call?

Ultragenyx will discuss its financial results and corporate updates for the quarter ended September 30, 2022.

When is Ultragenyx's Q3 2022 earnings call scheduled?

The earnings call is scheduled for November 2, 2022, at 5:00 PM ET.

Where can I find the Ultragenyx Q3 2022 earnings call webcast?

The live and replayed webcast will be available on Ultragenyx's official website.

What is Ultragenyx focusing on in its business strategy?

Ultragenyx is concentrating on developing therapies for serious rare and ultra-rare genetic diseases.

How long will the replay of the Q3 2022 earnings call be available?

The replay of the call will be available for one year after the event.